Fire in the Smoke: Battling Brain Tumors.
作者信息
Lim Michael, Jackson Christopher M
出版信息
Cerebrum. 2018 May 1;2018. eCollection 2018 May-Jun.
Abstract
.
摘要
相似文献
1
Fire in the Smoke: Battling Brain Tumors.
Cerebrum. 2018 May 1;2018. eCollection 2018 May-Jun.
2
Emerging immunotherapies for glioblastoma.
Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643.
3
Therapeutic gene modified cell based cancer vaccines.
Gene. 2013 Aug 10;525(2):200-7. doi: 10.1016/j.gene.2013.03.056. Epub 2013 Apr 6.
4
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Int J Cancer. 2016 Jan 1;138(1):187-94. doi: 10.1002/ijc.29686. Epub 2015 Jul 28.
5
The progress of immunotherapy for glioblastoma.
Hum Vaccin Immunother. 2015;11(11):2654-8. doi: 10.1080/21645515.2015.1081727.
6
Immunotherapy in human glioblastoma.
Rev Neurol (Paris). 2011 Oct;167(10):668-72. doi: 10.1016/j.neurol.2011.07.002. Epub 2011 Aug 31.
7
Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6.
8
[Immunotherapy in brain tumors].
Ann Pathol. 2017 Feb;37(1):117-126. doi: 10.1016/j.annpat.2016.12.001. Epub 2017 Jan 19.
9
Novel approaches and mechanisms of immunotherapy for glioblastoma.
Discov Med. 2014 Mar;17(93):145-54.
10
Therapeutic Immunization against Glioblastoma.
Int J Mol Sci. 2018 Aug 27;19(9):2540. doi: 10.3390/ijms19092540.
本文引用的文献
1
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. Epub 2018 Feb 7.
2
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
3
Vaccine-based immunotherapeutic approaches to gliomas and beyond.
Nat Rev Neurol. 2017 Jun;13(6):363-374. doi: 10.1038/nrneurol.2017.64. Epub 2017 May 12.
4
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Sci Transl Med. 2016 Dec 21;8(370):370ra180. doi: 10.1126/scitranslmed.aag2942.
5
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.
J Immunother Cancer. 2016 May 17;4:28. doi: 10.1186/s40425-016-0132-2. eCollection 2016.
6
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
J Clin Oncol. 2016 Jul 1;34(19):2206-11. doi: 10.1200/JCO.2016.66.6552. Epub 2016 Mar 21.
7
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.
8
Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.
Clin Cancer Res. 2016 Mar 1;22(5):1161-72. doi: 10.1158/1078-0432.CCR-15-1516. Epub 2015 Oct 21.
9
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
10
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Neuro Oncol. 2015 Jun;17(6):854-61. doi: 10.1093/neuonc/nou348. Epub 2015 Jan 13.
Zotero 插件